Loading stock data…
vTv Therapeutics Inc. (VTVT)
$36.27+1.19 (+3.39%)
Market ClosedLast close Jun 29
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
vTv Therapeutics Inc. in the Healthcare sector is trading at $36.27 with a market capitalization of $130M. Wall Street consensus targets $53.00 (6 analysts), implying a +46.1% move over the next 12 months. The stock is currently 18% below its 52-week high of $44.00, remaining 13.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +46.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $36.84M | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | $23.26M↑ | -$7.88M↑ | -$10.70M↓ | -$7.72M↓ | -$6.50M |
| Net Income | $24.13M↑ | -$7.14M↑ | -$8.70M↓ | -$6.05M↓ | -$5.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$129.74M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.50%
Volume
Today's trading volume
79,344
Recent News
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next
A week ago, vTv Therapeutics Inc. ( NASDAQ:VTVT ) came out with a strong set of quarterly numbers that could...
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, vTv Therapeutics (VTVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 31.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.